Clinical trials: Systolic Hypertension
Essential Hypertension
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
- Trial name
- ALIAS (NCT01042392)
- Testing
- Aliskiren, Ramipril
- Where
- 98 sites in France
- Volunteers
- 506 people
- Sponsor
- Novartis
Hypertension, Hypercholesterolemia
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.
- Trial name
- NCT07564726
- Testing
- Amlodipine, Ezetimibe/Rosuvastatin
- Where
- 21 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- Celltrion Pharm, Inc.
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Hypertension
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00364026
- Testing
- darusentan
- Sponsor
- Gilead Sciences
Isolated Systolic Hypertension
SER100 in Isolated Systolic Hypertension
Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.
- Trial name
- NCT01987284
- Testing
- SER100
- Where
- 7 sites in Finland, Hungary and 2 more
- Volunteers
- 17 people
- Sponsor
- Serodus AS
Hypertension
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)
A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension.
- Trial name
- NCT00140959
- Testing
- MK0954, losartan potassium/Duration of Treatment: 18 weeks, Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypertension,Essential, Systolic Hypertension
Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
This washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately.
- Trial name
- NCT05086523
- Testing
- Programmable Hypertension Control (BackBeat Moderato), Pacing (BackBeat Moderato)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 28 people
- Sponsor
- BackBeat Medical Inc
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00353912
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Novartis
Hypertension
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.
- Trial name
- NCT00386139
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 881 people
- Sponsor
- Novartis
Hypertension
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.
- Trial name
- NCT02172040
- Testing
- Over-encapsulated 10 mg amlodipine besylate tablet, Over-encapsulated 200 mg celecoxib capsule
- Where
- 10 sites in United Kingdom
- Volunteers
- 152 people
- Sponsor
- Kitov Pharmaceuticals, Ltd.
Essential Hypertension
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week…
- Trial name
- NCT06500689
- Testing
- Allisartan Isoproxil/Sustained-Release Indapamide, Allisartan Isoproxil
- Where
- 40 sites in China
- Volunteers
- 366 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Hypertension, Hypertrophy, Left Ventricular
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy.
- Trial name
- NCT00045994
- Testing
- ALT-711
- Volunteers
- 180 people
- Sponsor
- Synvista Therapeutics, Inc
Hypertension, Diabetes Mellitus
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting…
- Trial name
- ASTRIDE (NCT00787605)
- Testing
- Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- Novartis
Hypertension
AMISH : Aprovel for Management of Isolated Systolic Hypertension
To compare the antihypertensive efficacy and tolerability of irbesartan and irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus hydrochlorothiazide in the treatment of isolated systolic…
- Trial name
- NCT00264212
- Testing
- irbesartan and irbesartan-hydrochlorothiazide
- Where
- 8 sites in Chile, China and 6 more
- Volunteers
- 436 people
- Sponsor
- Sanofi
Hypertension
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
- Trial name
- ACCOMPLISH (NCT00170950)
- Testing
- Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 11,506 people
- Sponsor
- Novartis
Stage 2 Systolic Hypertension
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood…
- Trial name
- EXALT (NCT00931710)
- Testing
- valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
- Where
- United States
- Volunteers
- 488 people
- Sponsor
- Novartis